Elephas

elephas.com

Elephas is developing an innovative oncology platform that predicts response to immunotherapy using live tumor biopsies. The platform integrates various components to assess a tumor's response, aiming to improve cancer care by providing accurate predictive biomarkers. With a unique approach that preserves the tumor microenvironment, Elephas can predict treatment responses within 72 hours of biopsy, making it tumor-agnostic and applicable across various immunotherapies. The company is positioned to significantly enhance clinical decision-making and accelerate drug development in oncology.